Jingsong He (JingSong He)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 13

Top Topics

Acute Myeloid Leukemia

Multiple Myeloma

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Cancer medicine

Oxidative medicine and cellular longevity

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Lingling Wang, Lei Yang, Fangshu Guan, Jing Chen, Yuexin Cheng, Yuqing Miao, Jingsong He, Zhen Cai, He Huang, Yi Zhao
TP53 and KMT2D mutations associated with worse prognosis in peripheral T-cell lymphomas. Cancer medicine 13 (14) (2024)
Linlin Huang, Yi Zhong, Qingxiao Chen, Donghua He, Gaofeng Zheng, Yang Yang, Xiaoyan Han, Wenjun Wu, Yi Zhao, Yi Li, Li Yang, Zhen Cai, Jingsong He
The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients. Cancer biology & therapy 25 (1) (2024)
Xiaoyan Han, Xincheng Jiang, Jingsong He, Gaofeng Zheng, Yaqin Xiong, Yanling Wen, Yang Yang, Donghua He, Qingxiao Chen, Yi Zhao, Yi Li, Wenjun Wu, Zhen Cai
Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China. Cancer medicine 13 (9) (2024)
Dian Jin, Jingsong He, Haoguang Chen, Wenjun Wu, Xiaoyan Han, Jing Le, Wenxiu Shu, Qianqian Yang, Shanshan Pei, Zhen Cai, Donghua He
Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents. Cancer medicine 13 (14) (2024)
Dian Jin, Jingsong He, Haoguang Chen, Wenjun Wu, Xiaoyan Han, Jing Le, Wenxiu Shu, Qianqian Yang, Shanshan Pei, Zhen Cai, Donghua He
Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents. Cancer medicine 13 (14) (2024)
Xiaoyan Han, Xincheng Jiang, Jingsong He, Gaofeng Zheng, Yaqin Xiong, Yanling Wen, Yang Yang, Donghua He, Qingxiao Chen, Yi Zhao, Yi Li, Wenjun Wu, Zhen Cai
Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China. Cancer medicine 13 (9) (2024)
Lingling Wang, Lei Yang, Fangshu Guan, Jing Chen, Yuexin Cheng, Yuqing Miao, Jingsong He, Zhen Cai, He Huang, Yi Zhao
TP53 and KMT2D mutations associated with worse prognosis in peripheral T-cell lymphomas. Cancer medicine 13 (14) (2024)
Lingling Wang, Lei Yang, Fangshu Guan, Jing Chen, Yuexin Cheng, Yuqing Miao, Jingsong He, Zhen Cai, He Huang, Yi Zhao
TP53 and KMT2D mutations associated with worse prognosis in peripheral T-cell lymphomas. Cancer medicine 13 (14) (2024)
Tingting Yang, Binqian Jiang, Yi Luo, Yanmin Zhao, Guifang Ouyang, Jian Yu, Jianping Lan, Ying Lu, Xiaoyu Lai, Baodong Ye, Yi Chen, Lizhen Liu, Yang Xu, Pengfei Shi, Haowen Xiao, Huixian Hu, Qunyi Guo, Huarui Fu, Yishan Ye, Xinyu Wang, Jie Sun, Weiyan Zheng, Jingsong He, Yi Zhao, Wenjun Wu, Zhen Cai, Guoqing Wei, He Huang, Jimin Shi
Comparison of the prognostic predictive value of Molecular International Prognostic Scoring System and Revised International Prognostic Scoring System in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms. American journal of hematology (2023)
Lei Qiu, Yi Zhao, Yang Yang, He Huang, Zhen Cai, Jingsong He
Thymic rebound hyperplasia post-chemotherapy mistaken as disease progression in a patient with lymphoma involving mediastinum: a case report and reflection. BMC surgery 21 (1) (2021)
Enfan Zhang, Xi Huang, Jingsong He
Integrated bioinformatic analysis of HNF1A in human cancers. The Journal of international medical research 49 (3) (2021)
Xiuhua Wu, Yang Liu, Enfan Zhang, Jing Chen, Xi Huang, Haimeng Yan, Wen Cao, Jianwei Qu, Huiyao Gu, Ruyi Xu, Jingsong He, Zhen Cai
Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma through the P38/MAPK and Wnt/β-Catenin Signaling Pathways. Oxidative medicine and cellular longevity 2020 (2020)
XiaoYan Yue, Qingxiao Chen, Jingsong He
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. Cancer cell international 20 (1) (2020)